Interestingly, the technology is based on Radium and pioneered at The Norwegian Radium Hospital by Bruland and Roy H. Larsen (Larsen is currently a guest scientist at Department of Radiation Biology). The treatment utilizes the unique radiobiological and bone-seeking properties of the alpha-emitting radioisotope Radium-223 (AlpharadinR).
Professor Ã˜yvind S. Brulands home page - www.bruland.info
Bruland OS, Nilsson S, Fisher DR, Larsen RH.
High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?
Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6250s-6257s. (link to PubMed)
Lipton A, Berenson JR, Body JJ, Boyce BF, Bruland OS, Carducci MA, Cleeland CS, Clohisy DR, Coleman RE, Cook RJ, Guise TA, Pearse RN, Powles TJ, Rogers MJ, Roodman GD, Smith MR, Suva LJ, Vessella RL, Weilbaecher KN, King L.
Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference.
Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6209s-6212s. (link to PubMed)